Results 81 to 90 of about 7,686 (201)

Proprotein convertase subtilisin/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease

Frontiers in Cardiovascular Medicine
Background and aimsContrast-associated acute kidney injury (CA-AKI) may occur in patients undergoing medical procedures involving x-rays and radiocontrast media, potentially resulting in prolonged renal impairment.
Yu Ma, Yu Ma, Hui Fan, Wei Mi, Jing Ma, Yong Deng, Yijie Song, Ximing Li, Ximing Li   +8 more
doaj   +1 more source

Cholesterol‐lowering drug targets reduce risk of dementia: Mendelian randomization and meta‐analyses of 1 million individuals

Alzheimer's &Dementia, Volume 21, Issue 10, October 2025.
Abstract INTRODUCTION We tested whether genetically proxied non‐high‐density lipoprotein cholesterol (non‐HDL‐C)–lowering drug targets reduce risk of all‐cause dementia. METHODS We included 1,091,775 individuals from three prospective general population cohorts with individual‐level data and two consortia with summary‐level data.
Liv Tybjærg Nordestgaard, Aimee Hanson, Eleanor Sanderson, Emma Anderson, Venexia Walker, Anne Tybjærg‐Hansen, George Davey Smith, Børge G. Nordestgaard   +7 more
wiley   +1 more source

Experiencia del paciente en tratamiento con inhibidores de pcsk9 con el modelo de atención farmacéutica cmo [PDF]

, 2019
La Atención Farmacéutica clásica se basa en la identificación, resolución y prevención de los PRM, excluyendo como factor principal los problemas asociados al paciente.
Garcés Troncoso, Vanessa
core  

The Role of Genetics in Stroke Risk and Outcome: A Review of Current Evidence

Brain and Behavior, Volume 15, Issue 10, October 2025.
This study delineates the multiple pathways leading to stroke, encompassing genetic risk factors such as lipid/cholesterol metabolism, blood pressure regulation genes, and endothelial dysfunction. The report includes genetic pathways such as Val66Met polymorphism, prothrombin G20210A, interleukin‐6 and tumor necrosis factor gene variant, along with ...
Mega Obukohwo Oyovwi, Benneth Ben‐Azu, Ejayeta Jeroh, Faith B. Friday   +3 more
wiley   +1 more source

Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk [PDF]

, 2016
Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (
Asselbergs, Folkert W., Bakker, Paul I. W., Holmes, Michael V., Keating, Brendan J., Moore, Jason H., Palmer, Tom M., Swerdlow, Daniel I., Tragante, Vinicius   +7 more
core   +1 more source

ESVM Guideline on peripheral arterial disease [PDF]

, 2019
International ...
, , , Belch, Jill, Boc, Vinko, Brodmann, Marianne, Bulvas, Miroslav, Canning, Caitriona, Carpentier, Patrick H., Chraim, Ali, Colgan, Mary-Paula, Dimakakos, Evangelos, Dorigo, Walter, Frank, Ulrich, Gottsäter, Anders, Heiss, Christian, Houston, Graeme, Kahan, Thomas, Lawall, Holger, Lindstedt, Isak, Madaric, Juraj, Mahe, Guillaume, Martini, Romeo, Mazzolai, Lucia, Nikol, Sigrid, Olinic, Dan Mircea, Pernod, Giles, Poredoš, Pavel, Przywara, Stanislaw, Pécsvárady, Zsolt, Quéré, Isabelle, Righini, Marc, Roztocil, Karel, Schlager, Oliver, Stanek, Agata, Terlecki, Piotr, Vasic, Dragan, Visonà, Adriana, Wautrecht, Jean-Claude   +38 more
core   +5 more sources

Nutraceuticals as therapeutic agents for atherosclerosis [PDF]

, 2018
Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths.
Moss, Joe, Ramji, Dipak, Williams, Jessica   +2 more
core   +2 more sources

PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety

Frontiers in Neurology
BackgroundLipid-lowering therapies are mainstays in reducing recurrence after acute ischemic stroke (AIS). Evolocumab, a Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, is a promising lipid-lowering agent known to decrease LDL ...
Jonguk Kim, Uichan Hong, Cindy W. Yoon, Jin Woo Bae, Joung-Ho Rha, Hee-Kwon Park   +5 more
doaj   +1 more source

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

Cardiology and Therapy, 2019
Introduction The apolipoprotein A1 (apoA1) remnant ratio has been identified as an independent cardiovascular (CV) risk factor. Higher apoA1 remnant ratios may predict lower CV risk in some patients.
Heidi T. May, Joseph B. Muhlestein, Yuhui Ma, J. Antonio G. López, Blai Coll, John Nelson   +5 more
doaj   +1 more source

Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis

Reviews in Cardiovascular Medicine
Background: Direct comparisons between the drugs are limited, and the dosing remains debatable. Therefore, the study aims to indirectly compare the efficacy and safety of inclisiran, alirocumab, evolocumab, and evinacumab in lipid ...
Lin Zhang, Bin Li, Wei Chen, Wei Li, Huayun Yang, Diguang Pan   +5 more
doaj   +1 more source